Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385804 | 1.00 | FFAR1 (0.46) | FFAR1FFAR4PKMPIK3CDABL1 | |
| SCHEMBL29440624 | 0.85 | PKM (0.56) | PKMMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL972013 | 0.85 | PKM (0.56) | PKMMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL31314166 | 0.82 | FFAR1 (0.43) | FFAR1FFAR4PKMSCDSCD5 | |
| SCHEMBL1808652 | 0.81 | FFAR1 (0.48) | FFAR1FFAR4PKMMAPTMEN1 | |
| SCHEMBL546111 | 0.81 | TDP1 (0.38) | MEN1KMT2AALDH1A1HPGDL3MBTL1 | |
| SCHEMBL30294538 | 0.81 | FFAR1 (0.48) | FFAR1FFAR4PKMMAPTMEN1 | |
| SCHEMBL4749281 | 0.79 | FFAR1 (0.47) | FFAR1FFAR4SLC6A4GAA | |
| SCHEMBL30755347 | 0.79 | FFAR1 (0.47) | FFAR1FFAR4SLC6A4GAA | |
| Fluoride SCHEMBL28350549 | 0.79 | FFAR1 (0.47) | FFAR1FFAR4PKMMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038462-A2 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-114072398-B | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-4257588-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | Reistone Biopharma Company Limited (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20220213070-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-07-07 | — | — | US | disclosed |
| WO-2022117059-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | 瑞石生物医药有限公司 | 2022-06-09 | — | — | WO | disclosed |
| EP-3971180-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-23 | — | — | EP | disclosed |
| CN-114072398-A | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2020224396-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | 上海仕谱生物科技有限公司 | 2020-11-12 | — | — | WO | disclosed |
| CN-111909138-A | Compounds that inhibit TDG activity | 上海仕谱生物科技有限公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-101910179-B | Glucocorticoid receptor modulator and use method | LILLY CO ELI | 2013-06-19 | — | — | CN | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| CN-1199954-C | Benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2005-05-04 | — | — | CN | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| CN-1379764-A | Benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | FFAR1 94/4885FFAR4 274/4885PKM 4579/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | FFAR1 168/4885FFAR4 255/4885PKM 4177/4885 |
| US-20220213070-A1 | COMPOUNDS INHIBITING TDG ACTIVITY | TDO2, TFPI, PPIG | FFAR1 3866/4885FFAR4 4123/4885PKM 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.